Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;39(3):72-4.
doi: 10.18773/austprescr.2016.037. Epub 2016 Jun 1.

The challenge of costly drugs

Charles Denaro  1 , Jennifer Martin  2
Affiliations

The challenge of costly drugs

Charles Denaro et al. Aust Prescr. 2016 Jun.
No abstract available

Keywords: Pharmaceutical Benefits Scheme; cost-effectiveness of drugs; hepatitis C.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Charles Denaro is the Chair of the Queensland Health Medicines Advisory Committee. He currently serves on the Fabry Disease Advisory Boards for Genzyme and Shire, and was previously on the advisory boards of CSL and Menarini. He has received honoraria for speaking by Mundi Pharma and Shire, and was involved in a number of phase III trials for new oral anticoagulants – Bayer, Pfizer and Boehringer Ingelheim – and received sponsorship to attend conferences by Novartis, Sanofi, MSD, Vifor Pharma, Menarini and Astra Zeneca.

Conflict of interest: Jennifer Martin has been a member of the Pharmaceutical Benefits Advisory Committee and Queensland Health Medicines Advisory Committee. She is currently an Advisor to the Ministry of Health (New Zealand) Pharmacology and Therapeutic Advisory Committee and an external evaluator for the Therapeutic Goods Administration.

Comment in

  • The challenge of costly drugs.
    Hillock N. Hillock N. Aust Prescr. 2016 Oct;39(5):149. doi: 10.18773/austprescr.2016.072. Epub 2016 Oct 1. Aust Prescr. 2016. PMID: 27789921 Free PMC article. No abstract available.

References

    1. The Pharmaceutical Benefits Scheme. PBS statistics. Canberra: Department of Health; 2015. www.pbs.gov.au/info/browse/statistics [cited 2016 May 1]
    1. Babar Z, Vitry A. Differences in Australian and New Zealand medicines funding policies. Aust Prescr 2014;37:150-1. 10.18773/austprescr.2014.059 - DOI
    1. National Medicines Policy. 2000. Canberra: Department of Health and Ageing; 1999. www.health.gov.au/internet/main/ publishing.nsf/Content/B2FFBF72029EEAC8... [cited 2016 May 1]
    1. The Pharmaceutical Benefits Scheme. Crizotinib; 200 mg capsule, 60 and 250 mg capsule, 60; Xalkori. Canberra: Department of Health; 2015. www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-11/... [cited 2016 May 1]
    1. Kind P, Lafata JE, Matuszewski K, Raisch D. The use of QALYs in clinical and patient decision-making: issues and prospects. Value Health 2009;12 Suppl 1:S27-30. 10.1111/j.1524-4733.2009.00519.x - DOI - PubMed

LinkOut - more resources